Institut-Curie, Servier Extend Triple-negative Breast Cancer Partnership | GenomeWeb

NEW YORK (GenomeWeb News) — Curie-Cancer, which leads Institut Curie's industry partnerships, and the French drug developer Servier have extended an ongoing partnership focused on breast cancer research for another three years, they said today.
Institut Curie and Servier teamed up in 2005 to launch the program, which aims to identify therapeutic targets for treating triple-negative breast cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.